Authors
Latest:
Revolutionizing Treatment For Duchenne Muscular Dystrophy with Gene Editing: Courtney Young, PhDThe co-founder and chief executive officer of MyoGene Bio talked about the advantages of gene editing over traditional gene therapy as a long term treatment for neuromuscular diseases at MDA’s 2023 conference. [WATCH TIME: 3 minutes]
Latest:
The Implementation of Platform Trials for ALS Research: Melanie Quintana, PhDThe senior statistical scientist and director of consulting at Berry Consultants talked about innovative clinical trial design in ALS research at the 2023 MDA conference. [WATCH TIME: 5 minutes]
Latest:
Aparna V.R. Polavarapu, MD: Early Treatment for Infantile SpasmsThe pediatric neurologist at Montefiore Health System explains the importance of treating infantile spasms as early as possible and how it may impact outcomes.
Latest:
Key Takeaways From ANNEXA-I StudyDr Connolly highlights the cautious patient selection and the significance of reducing hematoma expansion for improved outcomes in cases of intracerebral hemorrhage (ICH) associated with the use of a reversal agent for factor Xa inhibitors.
Latest:
Mission Behind Cure CMD’s Research Roundtable, Efforts Around CMDs: Rachel AlvarezThe executive director of Cure CMD discussed efforts being done to bring the stakeholder community together and improve the care for patients with congenital muscular dystrophies. [WATCH TIME: 4 minutes]
Latest:
Concluding Thoughts on Biosimilars in Multiple SclerosisAmy Perrin Ross, APN, Patricia Melville, NP-C, Aliza Ben-Zacharia, PhD, DNP, ANP-BC, and John Kramer, PA-C share their advice for facilitating uptake of biosimilars in clinical practices.
Latest:
Steven Arnold, MD: Assessing AMX0035 Efficacy in Alzheimer DiseaseThe managing director of the Interdisciplinary Brain Center at Massachusetts General Hospital discussed the process of determining the best situations for use of AMX0035.
Latest:
Role of Alpha-Synuclein in Accurate and Early Diagnosis of Parkinson Disease: Sameea Husain-Wilson, DOThe neurologist and director of movement disorder neurology at the Marcus Neuroscience Institute discussed how the Syn-One test utilizes alpha-synuclein and what this biomarker adds to the diagnosis of Parkinson disease. [WATCH TIME: 3 minutes]
Latest:
AUPN 2022 Veterans Health Administration WorkshopGlenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, multiple sclerosis, epilepsy and seizures, and headache. [WATCH TIME: 1 hour, 52 minutes]
Latest:
Expanding KP1077’s Clinical Program to Address Narcolepsy and Other Conditions: Christal MickleThe cofounder and chief product development officer of Zevra Therapeutics talked about the phase 1 clinical trial of KP1077 for narcolepsy and potentially using it to treat other conditions. [WATCH TIME: 5 minutes]
Latest:
Differences in Approaches to Pediatric and Adult Sleep Disorders: Jodi A. Mindell, PhDThe associate director of the Sleep Center at Children’s Hospital of Philadelphia detailed the similarities and differences in how sleep disorders are viewed between children and adults. [WATCH TIME: 4 minutes]
Latest:
Lessons Learned From Aducanumab Experience and Antiamyloid Therapies: Ian KremerThe executive director of the Lead (Leaders Engaged on Alzheimer’s Disease) Coalition provided thoughts on the journey and lessons learned from aducanumab (Aduhelm) following Biogen’s decision to remove it from market. [WATCH TIME: 8 minutes]
Latest:
Improving Alzheimer Diagnosis With Innovative Blood-Based Biomarker Tests and BD-Tau: Mike Miller, PhDThe chief operating officer at Quanterix Corporation talked about pioneering ultra-sensitive blood biomarkers for Alzheimer clinical diagnosis, aiming to enhance detection of brain-derived tau and amyloid status with innovative assays. [WATCH TIME: 4 minutes]
Latest:
CMSC Live: 2024 Annual Meeting Day 2Host Jeffrey Wilken, PhD, chats with Fred Lublin, MD; Brian Hutchinson, PT, MSCS; and Robert Motl, PhD, about the second day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.
Latest:
Consistent Real-World Efficacy of Ofatumumab Therapy for Multiple Sclerosis: Jason Freeman, MD, MBAThe medial director of Novartis talked about findings from a real-world study assessing ofatumumab treatment for multiple sclerosis presented at the 2024 ACTRIMS Forum. [WATCH TIME: 3 minutes]
Latest:
Standardizing Clinical Practice for End of Life Care in Neuromuscular Diseases: Lauren Treat, MDThe child neurologist at the University of Colorado School of Medicine talked about her presentation on end of life care for patients with neuromuscular diseases at the 2023 MDA conference. [WATCH TIME: 5 minutes]
Latest:
Future Directions for the Management of MigraineBradley Torphy, MD, and Julio R. Vieira, MD, share unmet needs and clinical pearls for the management of migraine.
Latest:
Unveiling the Role of Estrogen in Women's Cognitive Health: Lisa Mosconi, PhDThe director of the Weill Cornell Women’s Brain Initiative discussed emerging research that highlight the significant impact of sex hormones on women's brain health, and how it influences conditions like Alzheimer disease. [WATCH TIME: 8 minutes]
Latest:
Advice for Physicians and the Multiple Sclerosis CommunityThe panel shares final advice for the multiple sclerosis community.
Latest:
Intervening Early in MS With Exercise: Ulrik Dalgas, PhDThe professor of public health and sports science at Aarhus University shared his perspective on the potential to modify multiple sclerosis disease progression with lifestyle interventions. [WATCH TIME: 2 minutes]
Latest:
Identifying Small Clinical Characteristics to Facilitate Early Myasthenia Gravis Diagnosis: Judith Thompson, PharmD, MPH, CPHQThe rare disease population health strategy lead at UCB provided clinical insight on some of the unique challenges of diagnosing myasthenia gravis, and some of the early signs clinicians and non-specialists should look out for. [WATCH TIME: 3 minutes]
Latest:
Unveiling the Connection Between Migraine and the Gut: Daping Yang, PhDThe postdoctoral researcher at Harvard Medical School discussed the relationship between sensory neurons and the neuropeptide CGRP in regulating gut immunity. [WATCH TIME: 6 minutes]
Latest:
Patient-Clinician Conversations Regarding Drug-Resistant Epilepsy, Surgical Options: Alex Whiting, MDThe director of epilepsy surgery at Allegheny Health Network provided insight on the early discussions between patients with drug resistant epilepsy and clinicians seeking to find beneficial treatment strategies. [WATCH TIME: 3 minutes]
Latest:
Ways to Optimize Trials for ALS Drug Development: Richard Bedlack, MD, PhD, MSThe director of the Duke ALS Clinic at Duke Health discussed the advances in drug development for ALS and ways to evolve future trials to get optimal therapeutic benefit. [WATCH TIME: 3 minutes]
Latest:
Categorizing Biomarker Criteria for Alzheimer Disease Diagnosis and Staging: Clifford R. Jack Jr., MDThe neuroradiologist at Mayo Clinic discussed the categorization of biomarkers for Alzheimer disease, focusing on core biomarkers specific to the disease and those reflecting related pathologies. [WATCH TIME: 8 minutes]
Latest:
Continued Evolution of Deep Brain Stimulation in Neurology: Jonathan Jagid, MD; Brian Noga, PhDA pair of neurologists from the University of Miami Miller School of Medicine provided insight on the various ways deep brain stimulation has changed and the potential treatment opportunities that lie ahead. [WATCH TIME: 4 minutes]
Latest:
Effectiveness of Zavegepant in Treating Migraine With and Without Aura: Timothy Smith, MDThe chief executive officer and president of Study Metrics Research provided commentary on a large-scale analysis further demonstrating efficacy and safety of zavegepant, regardless of aura status. [WATCH TIME: 3 minutes]
Latest:
Clinical Validation and Real-World Impact of PrecivityAD2 Test for Alzheimer Diagnosis: Joel B. Braunstein, MDThe CEO at C2N Diagnostics talked about the clinical utility of the company’s PrecivityAD2 test, which uses the p-tau 217 biomarker and amyloid-β measurements, to increase diagnostic confidence and influence treatment decisions in Alzheimer disease. [WATCH TIME: 7 minutes]
